Seth M. Engel ([email protected])

Most-Favored Nation Drug Pricing: What U.S. Pricing Initiatives Mean for International Commercial Contracts

The Trump administration’s most-favored nation agreements with major pharmaceutical companies and recent initiatives by the Centers for Medicare & Medicaid Services — including the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) model, proposed GUARD (Guarding U.S. Medicare Against Rising Drug Costs) model, and proposed GLOBE (Global Benchmark for Ef